Myocardial Infarction Market Analysis & Forecast: 2026-2033

Myocardial Infarction Market Size and Share Analysis- 2026 To 2033

The Myocardial Infarction Market size is anticipated to grow at a CAGR of 5.9% with USD 2.42 Bn in 2026 and is expected to reach USD 3.61 Bn by 2033. The market growth is primarily driven by the increasing prevalence of cardiovascular diseases, rising incidence of acute myocardial infarction, growing geriatric population, and increasing awareness regarding early diagnosis and timely treatment. According to a 2025 global cardiovascular projection study published in a peer-reviewed journal, cardiovascular disease prevalence is projected to increase by nearly 90% between 2025 and 2050, while annual cardiovascular deaths are expected to rise from 20.5 million to 35.6 million.

Key Takeaways

• Antiplatelet agents segment is anticipated to dominate the market at 31.8% in 2026. This growth can be accounted for because they serve as the first line of treatment in the treatment and secondary prevention of myocardial infarction. Antiplatelets such as aspirin and P2Y12 inhibitors are usually recommended in order to prevent thrombosis after the development of acute coronary syndrome. According to 2025 American Heart Association heart disease and Stroke Statistics Update, Ischemic heart disease is the most prevalent cause of mortality from heart disease globally.
• Oral segment is expected to dominate with 68.9% in 2026. The oral segment’s dominance will be fuelled by the increasing demand for oral medicines that help manage patients with myocardial infarction in the long term, which includes anti-platelet drugs, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, and others. As per the 2025 ESC Guidelines for the management of Acute Coronary Syndromes, long-term oral medicine therapy is the gold standard for reducing recurrence and improving long-term survival of myocardial infarction patients.
• The hospital pharmacies segment is expected to dominate the market by 2026, growing at a value of 56.4%. This growth is attributed to the fact that most patients suffering from myocardial infarctions need to be hospitalized immediately for diagnosis and treatment because of the use of thrombolytic agents, anticoagulants, glycoprotein IIb/IIIa inhibitors, and various other medications. As stated in the guidelines of 2023 ESC (European Society of Cardiology), all patients with suspected acute coronary syndromes should be treated rapidly in a hospital capable of providing reperfusion therapy and evidence-based pharmacological management.
• The North American region is expected to dominate the global myocardial infarction market by accounting for a share of 39.8% by 2026. The dominance of the region can be attributed to the high prevalence of cardiovascular diseases in the region along with extensive use of advanced cardiology diagnostic and interventional devices, favorable reimbursement scenarios, and adherence to evidence-based treatment guidelines. According to CDC of the USA, about 805,000 Americans suffer from heart attacks every year with about 605,000 occurring for the first time and about 200,000 being repeat occurrences.

Rising Burden of Cardiovascular Diseases and Heart Attacks is Driving the Myocardial Infarction Market

The rising number of cases of cardiovascular diseases (CVDs) and myocardial infarction all around the world are some of the key reasons for the increase in the market share of myocardial infarction. There has been an increase in the incidence of conditions like hypertension, diabetes, obesity, smoking, and sedentary lifestyles which have increased the number of cases prone to suffer from heart attacks.

According to a study carried out in 2025 in the European Heart Journal, there is a high prevalence of obesity in patients suffering from myocardial infarction and an increased risk of developing negative cardiovascular events, especially among those who suffer from diabetes.

In November 2025, Amgen announced positive Phase 3 VESALIUS-CV trial of Repatha® (evolocumab) that showed Repatha decreased the risk of first major adverse cardiovascular events by 25% and the risk of first myocardial infarction by 36% in high-risk patients without history of myocardial infarction or stroke, when administered with a lipid-lowering regimen.

Advancements in Reperfusion Therapies and Guideline-Directed Cardiac Care are Accelerating Market Growth

Increasing innovations in the field of revascularization therapy, interventional cardiology, and pharmacologic treatment are rapidly propelling the market for myocardial infarction. It is because of the increasing prevalence of primary PCI, high-sensitivity cardiac markers, and antiplatelet and anticoagulation medicines that have enhanced survival chances.

According to the 2024 ESC EuroHeart Registry, PCI continues to be the most common method used in Europe to restore coronary blood flow, as the hospitals that participated in the survey showed compliance to the recommended guidelines regarding reperfusion in STEMI patients.

In June 2024, Faraday Pharmaceuticals announced the completion of patient enrollment in its pivotal Phase 3 Iocyte AMI-3 trial evaluating FDY-5301 for patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

Current Events and Their Impact on the Myocardial Infarction Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Antiplatelet Agents Acquiring the Largest Share?

On the basis of drug class, the antiplatelet agents segment is projected to account for the largest myocardial infarction market share of 31.8% in 2026. The segment’s growth is owing to its critical role as the first-line therapy for acute myocardial infarction and secondary prevention of recurrent cardiovascular events. Antiplatelet agents such as aspirin and P2Y12 inhibitors are standard components of dual antiplatelet therapy (DAPT), which is widely recommended in clinical practice guidelines for reducing thrombosis risk after myocardial infarction.

According to a 2025 analysis published in The Lancet Cardiovascular Medicine, early dual antiplatelet therapy after acute myocardial infarction reduces the risk of recurrent major adverse cardiovascular events (MACE) by approximately 20% compared with single antiplatelet therapy, reinforcing its central role in post-infarction management and long-term secondary prevention strategies.

In October 2025, Alembic Pharmaceuticals Limited received U.S. FDA final approval for its Ticagrelor Tablets (60 mg), a generic version of AstraZeneca’s Brilinta. Ticagrelor is a key P2Y12 receptor inhibitor widely used as part of dual antiplatelet therapy (DAPT) for patients with acute coronary syndrome (ACS) and myocardial infarction (MI) to reduce the risk of cardiovascular death, recurrent myocardial infarction, and stroke.

Which Route of Administration dominates the market? 

To learn more about this report, Request Free Sample

On the basis of route of administration, the oral segment is set to lead the myocardial infarction market with a 68.9% share in 2026. The segment’s dominance is driven by the widespread use of oral therapies for long-term secondary prevention following myocardial infarction, including antiplatelet agents, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and lipid-lowering agents. Oral administration is preferred due to its ease of use, patient compliance, and suitability for chronic disease management after hospital discharge.

According to the European Heart Journal, Cardiovascular Pharmacotherapy (2025) based on the SWEDEHEART registry confirmed that 95–97% of myocardial infarction patients fill prescriptions for key secondary prevention medications (including oral agents such as aspirin, statins, beta-blockers, and ACE/ARB therapy) at discharge, highlighting near-universal adoption of oral pharmacotherapy immediately after MI.

In June 2026, Bayer announced that its oral Factor XIa inhibitor asundexian has entered European Medicines Agency (EMA) regulatory review for the prevention of recurrent ischaemic stroke in patients with prior non-cardioembolic stroke or transient ischaemic attack (TIA).

Hospital Pharmacies Hold the Largest Share

On the basis of distribution channel, the hospital pharmacies segment is projected to lead with a 56.4% share in 2026. The segment’s growth is owing to the fact that most myocardial infarction cases require immediate hospitalization for emergency diagnosis, reperfusion therapy, and intensive pharmacological management. Hospital pharmacies play a central role in dispensing critical medications such as thrombolytics, anticoagulants, antiplatelet agents, and glycoprotein IIb/IIIa inhibitors during acute care settings.

According to OECD healthcare pharmaceutical distribution data (official health system analysis), hospitals play a critical role in drug delivery systems, particularly for acute care conditions, where medicines are administered directly during inpatient treatment rather than through retail channels.

In July 2025, Norton Clark Hospital announced a $7 million renovation of its cardiac catheterization (cath) laboratory along with the installation of an advanced CT scanner with enhanced cardiovascular imaging capabilities.

Myocardial Infarction Market Trends

• High-sensitivity troponin adoption is transforming early MI diagnosis and increasing case detection rates globally. Modern hs-cTn assays allow detection of myocardial injury within 1–3 hours, improving emergency diagnosis and expanding treated patient pools. Clinical evidence shows troponin testing has now nearly replaced CK-MB as the gold standard biomarker for MI diagnosis due to superior sensitivity and specificity.
• Increasing prevalence of type 2 myocardial infarction and myocardial injury is expanding the diagnosed MI population. High-sensitivity troponin use has led to improved identification of non–ST-elevation MI and myocardial injury cases, which were previously underdiagnosed, increasing demand for diagnostic and therapeutic interventions.
• Increasing guideline harmonization is standardizing MI treatment protocols globally. ACC/AHA and ESC guidelines emphasize rapid biomarker testing, immediate antiplatelet therapy, and PCI-based intervention, driving uniform adoption of evidence-based MI care pathways across hospitals.

Regional Insights 

To learn more about this report, Request Free Sample

North America Dominates the Myocardial Infarction Market

North America is projected to dominate the global myocardial infarction market with an estimated market share of 39.8% in 2026. The region’s dominance is driven by a high burden of cardiovascular diseases, advanced emergency cardiac care infrastructure, widespread availability of percutaneous coronary intervention (PCI) facilities, and strong adoption of guideline-directed medical therapy.

In patients with myocardial infarction, the pooled prevalence of depression is 25.9% and anxiety is 9.1% globally, indicating a substantial post-MI psychological disease burden relevant to high-income regions such as North America where diagnosis rates are higher due to advanced screening systems.

In June 2026, Merck KGaA announced the launch of Saturnus Bio, a build-to-buy biotechnology company created in collaboration with Versant Ventures.

Asia Pacific is the Fastest-Growing Myocardial Infarction Market

Asia Pacific is expected to register the fastest growth in the myocardial infarction market during the forecast period, driven by a rapidly increasing burden of cardiovascular diseases, aging population, and rising prevalence of lifestyle-related risk factors such as diabetes, obesity, hypertension, and smoking.

According to the World Heart Federation (2025 World Heart Report), over 60% of global cardiovascular deaths occur in the Asia Pacific region, with countries such as China and India contributing significantly to the disease burden due to large population size and rising cardiometabolic risk factors.

In June 2026, FV Hospital in Ho Chi Minh City, Vietnam was ranked among the Best Specialised Hospitals in Asia-Pacific 2026 by Newsweek in collaboration with Statista.

United States Myocardial Infarction Market Trends

The U.S. myocardial infarction market is experiencing strong growth due to a high prevalence of cardiovascular diseases, advanced emergency cardiac care infrastructure, and widespread adoption of evidence-based treatment guidelines. In addition, cardiovascular diseases remain the leading cause of death in the U.S., accounting for about 1 in every 3 deaths, reinforcing continuous demand for hospital-based emergency care, percutaneous coronary intervention (PCI), and long-term pharmacological therapy.

In November 2025, Aspire Biopharma (U.S.) submitted a pre-IND application to the FDA for a fast-acting sublingual aspirin formulation designed for suspected acute myocardial infarction (heart attack).

China Myocardial Infarction Market Trends

China’s myocardial infarction market is expanding rapidly due to increasing prevalence of cardiovascular diseases, aging population, and rapid healthcare system modernization. According to the World Heart Federation (2025 World Heart Report), cardiovascular diseases account for over 40% of total deaths in China, with ischemic heart disease and myocardial infarction representing a major and growing disease burden.

Who are the Major Companies in Myocardial Infarction Industry

Some of the major key players in Myocardial Infarction Market are Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.

Key News

• In April 2026, Bristol Myers Squibb and Pfizer announced a collaboration with Mark Cuban Cost Plus Drug Company to make Eliquis (apixaban) available directly through the Cost Plus Drugs platform.
• In June 2026, Johnson & Johnson MedTech announced the initiation of the SKYWARD Investigational Device Exemption (IDE) clinical program evaluating the Shockwave™ SkyRunner Carotid Intravascular Lithotripsy (IVL) System, a first-of-its-kind device designed to treat calcified carotid arteries prior to carotid artery stenting.

Market Report Scope 

Analyst Opinion

• The Myocardial Infarction Market is witnessing steady growth due to the rising burden of cardiovascular diseases and increasing adoption of evidence-based therapies. According to the American Heart Association (AHA) 2025 heart disease and Stroke Statistics Update, cardiovascular disease remains the leading cause of death globally, accounting for over 20.5 million deaths annually, reinforcing the long-term demand for myocardial infarction diagnosis, intervention, and secondary prevention.
• Advancements in emergency cardiac care and interventional cardiology are significantly improving myocardial infarction outcomes. The 2025 ACC/AHA Guideline for Acute Coronary Syndromes emphasizes rapid diagnosis, timely primary percutaneous coronary intervention (PCI), and optimized antiplatelet and lipid-lowering therapy to improve survival and reduce recurrent cardiovascular events, thereby accelerating the adoption of advanced myocardial infarction treatment strategies.
• Improved survival following acute myocardial infarction is increasing the need for long-term cardiovascular management. According to a June 2025 Journal of the American Heart Association analysis, age-adjusted heart attack death rates in the United States have declined by nearly 90% since 1970, primarily due to advances in reperfusion therapies, preventive medications, and acute cardiac care. As more patients survive myocardial infarction, the demand for long-term secondary prevention therapies, cardiac rehabilitation, and continuous monitoring is expected to grow substantially.

Market Segmentation

• By Drug Class (Revenue, USD Bn, 2021-2033)
  • Antiplatelet Agents
  • Glycoprotein IIb/IIIa Inhibitors
  • Antithrombotic Agents
  • Beta-adrenergic Blockers
  • Vasodilators
  • Angiotensin-converting Enzyme (ACE) Inhibitors
  • Angiotensin-receptor Blockers
  • Analgesics
  • Thrombolytics
• By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Oral
  • Injectable
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

Cardiologists

• Interventional cardiologists
• Emergency medicine physicians
• Hospital pharmacists
• Cardiac surgeons
• Catheterization laboratory (Cath Lab) directors
• Clinical pharmacists
• Hospital administrators
• Cardiovascular researchers
• Key opinion leaders (KOLs) in cardiovascular medicine
• Medical device distributors

Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Organisation for Economic Co-operation and Development (OECD)
• European Medicines Agency
• U.S. Food and Drug Administration
• National Center for Cardiovascular Diseases (NCCD)

Magazines

• Cardiology Today
• Cardiovascular Business
• MedTech Dive
• Pharmaceutical Technology (PharmTech)
• Cardiovascular News

Journals

• Circulation
• Journal of the American College of Cardiology
• European Heart Journal
• Journal of the American Heart Association
• The Lancet
• BMJ Public Health

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• USA Today
• The Guardian

Associations

• American Heart Association
• American College of Cardiology
• European Society of Cardiology
• World Heart Federation
• Society for Cardiovascular Angiography & Interventions

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Government Health Ministry Publications
• Clinical Trial Registries such as ClinicalTrials.gov
• U.S. FDA Drug Approval Database
• EMA Medicine Assessment Reports
• WHO Global Health Observatory
• CDC National Center for Health Statistics

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years